Reversal of thermal hyperalgesia in a rat partial sciatic nerve ligation model by Prosaptide TX14(A).
We used the partial sciatic nerve ligation (PSL) model of Seltzer to assess thermal hyperalgesia after administration of Prosaptide 14-mer, TX14(A). At a dose of 200 microg/kg in Wistar rats, subcutaneous delivery of TX14(A) reversed thermal hyperalgesia at 3 and 24 h. Values declined at 48 h and returned to baseline at 72 h. A dosing study of TX(14)A gave a dependent response with 100 microg/kg having a similar potency to the 200 microg/kg study with 50 and 10 microg/kg responding somewhat lower. When TX(14)A was administered every fourth day for 12 days at 100 microg/kg, 24 h post injection values returned to baseline each time. Our results suggest that Prosaptide may have potential for therapeutic use in neuropathic pain syndromes in humans.
Otero
D A
DA
Department of Neuroscience, University of California, San Diego, La Jolla 92093-0634, USA.
Conrad
B
B
O'Brien
J S
JS
D000595:Amino Acid Sequence; D000818:Animals; D004305:Dose-Response Relationship, Drug; D006358:Hot Temperature; D006930:Hyperalgesia / Q000503:physiopathology* / Q000517:prevention & control / Q000628:therapy*; D008969:Molecular Sequence Data; D009414:Nerve Growth Factors / Q000737:chemistry / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D012584:Sciatic Nerve / Q000502:physiology / Q000503:physiopathology*; D013997:Time Factors
D009414:Nerve Growth Factors; C101246:prosaptide